Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
RGT-075 by Qilu Regor Therapeutics for Obesity: Likelihood of Approval
RGT-075 is under clinical development by Qilu Regor Therapeutics and currently in Phase II for Obesity. According to GlobalData, Phase...